Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
|Videos|February 14, 2018
Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC
Author(s)David R. Wise, MD, PhD
David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).
Advertisement
David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).
Advertisement
Related to this article
Focal therapy for prostate cancer has evolved over 2 decades, with advances in imaging, patient selection, treatment modalities, and clinical trials.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sevabertinib for Advanced HER2 TKD–Mutated Nonsquamous NSCLC
2
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
3
Micvotabart Pelidotin Monotherapy Yields Responses in Pretreated Recurrent/Metastatic HNSCC
4
Dabogratinib Elicits Responses in FGFR3+ Low-Grade Intermediate-Risk NMIBC
5